Chronic infection can lead to serious long-term health issues, such as cirrhosis and liver cancer. While there is currently no complete cure for hepatitis B and C, available treatments can control the ...

The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) on November 15 and set a price ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VIR stock, giving a Buy rating today.Don't Miss our Black ...

The safety profile of the treatments remained consistent ... effort by Vir Biotechnology to develop a functional cure for chronic hepatitis B, which affects millions worldwide and can lead to ...

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...

50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...

The safety profile of the treatments remained consistent with previous studies ... The MARCH Phase 2 trial is part of a broader effort by Vir Biotechnology to develop a functional cure for chronic ...